JP2018523709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523709A5 JP2018523709A5 JP2018527851A JP2018527851A JP2018523709A5 JP 2018523709 A5 JP2018523709 A5 JP 2018523709A5 JP 2018527851 A JP2018527851 A JP 2018527851A JP 2018527851 A JP2018527851 A JP 2018527851A JP 2018523709 A5 JP2018523709 A5 JP 2018523709A5
- Authority
- JP
- Japan
- Prior art keywords
- acute
- brain injury
- pharmaceutically acceptable
- acceptable salt
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029028 brain injury Diseases 0.000 claims description 78
- 150000003839 salts Chemical class 0.000 claims description 41
- 208000028389 Nerve injury Diseases 0.000 claims description 40
- 230000008764 nerve damage Effects 0.000 claims description 40
- 230000001154 acute effect Effects 0.000 claims description 29
- 210000004556 brain Anatomy 0.000 claims description 25
- 208000024891 symptom Diseases 0.000 claims description 20
- 230000006931 brain damage Effects 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 16
- 206010021143 Hypoxia Diseases 0.000 claims description 15
- 206010002660 Anoxia Diseases 0.000 claims description 10
- 241000976983 Anoxia Species 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 10
- 241000577218 Phenes Species 0.000 claims description 10
- 230000007953 anoxia Effects 0.000 claims description 10
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims description 8
- 201000001326 acute closed-angle glaucoma Diseases 0.000 claims description 8
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 206010013647 Drowning Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 230000006999 cognitive decline Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000009514 concussion Effects 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000007576 microinfarct Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000002980 postoperative effect Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010039203 Road traffic accident Diseases 0.000 claims description 2
- PBHFNBQPZCRWQP-AZUAARDMSA-N [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@H]1[C@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-AZUAARDMSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 206010008513 Child maltreatment syndrome Diseases 0.000 claims 1
- 208000002108 Shaken Baby Syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 208000025480 CHILD syndrome Diseases 0.000 description 4
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000035939 shock Effects 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205431P | 2015-08-14 | 2015-08-14 | |
| US62/205,431 | 2015-08-14 | ||
| PCT/US2016/046794 WO2017030968A1 (en) | 2015-08-14 | 2016-08-12 | Methods of treatment or prevention of acute brain or nerve injuries |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523709A JP2018523709A (ja) | 2018-08-23 |
| JP2018523709A5 true JP2018523709A5 (enExample) | 2019-09-19 |
| JP6862446B2 JP6862446B2 (ja) | 2021-04-21 |
Family
ID=56801810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527851A Active JP6862446B2 (ja) | 2015-08-14 | 2016-08-12 | 急性の脳または神経損傷の治療または予防の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12042482B2 (enExample) |
| EP (1) | EP3334425B1 (enExample) |
| JP (1) | JP6862446B2 (enExample) |
| CN (1) | CN107921024B (enExample) |
| AU (1) | AU2016309815B2 (enExample) |
| CA (1) | CA2994974C (enExample) |
| DK (1) | DK3334425T3 (enExample) |
| TW (1) | TW201717938A (enExample) |
| WO (1) | WO2017030968A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201717938A (zh) | 2015-08-14 | 2017-06-01 | Ｑｒ製藥股份有限公司 | 治療或預防急性腦部或神經損傷的方法 |
| EP3654957A4 (en) | 2017-05-24 | 2021-06-23 | Annovis Bio, Inc. | PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| WO1999002154A1 (en) | 1997-07-09 | 1999-01-21 | Axonyx | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
| DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| WO2002048150A2 (en) | 2000-11-02 | 2002-06-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
| US20040024043A1 (en) | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EP1617844A4 (en) | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| US20050013869A1 (en) | 2003-07-18 | 2005-01-20 | Chaw Cheng Shu | Sustained release formulation for carbamates and a method therefor |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| WO2005091987A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| WO2005089746A1 (en) | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
| EP1604686A1 (en) | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| WO2008134618A2 (en) | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
| WO2010117727A2 (en) | 2009-03-30 | 2010-10-14 | The General Hospital Corporation | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| TW201717938A (zh) | 2015-08-14 | 2017-06-01 | Ｑｒ製藥股份有限公司 | 治療或預防急性腦部或神經損傷的方法 |
-
2016
- 2016-08-12 TW TW105125790A patent/TW201717938A/zh unknown
- 2016-08-12 DK DK16757422.7T patent/DK3334425T3/da active
- 2016-08-12 EP EP16757422.7A patent/EP3334425B1/en active Active
- 2016-08-12 CN CN201680046586.2A patent/CN107921024B/zh active Active
- 2016-08-12 WO PCT/US2016/046794 patent/WO2017030968A1/en not_active Ceased
- 2016-08-12 CA CA2994974A patent/CA2994974C/en active Active
- 2016-08-12 AU AU2016309815A patent/AU2016309815B2/en active Active
- 2016-08-12 US US15/751,337 patent/US12042482B2/en active Active
- 2016-08-12 JP JP2018527851A patent/JP6862446B2/ja active Active
-
2024
- 2024-06-18 US US18/746,815 patent/US20250000846A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021075556A5 (enExample) | ||
| CA2236368C (en) | Sublingual and buccal administration of selegiline | |
| CA2882407C (en) | Anticholinergic neuroprotective composition and methods | |
| JP2015510941A5 (enExample) | ||
| JP2018035197A5 (enExample) | ||
| HRP20140131T1 (hr) | Lijeäśenje neuroloških poremeä†aja na bazi baklofena i akamprozata | |
| WO2018144551A3 (en) | D-methadone and its derivatives for use in the treatment of disorders of the nervous system | |
| JP2014505688A5 (enExample) | ||
| WO2009044392A3 (en) | Novel sirna structures | |
| SI2470168T1 (en) | Procedures for the prevention and treatment of brain ischemia | |
| JP2024112859A5 (enExample) | ||
| JP2019534327A5 (enExample) | ||
| JP2021080269A5 (enExample) | ||
| JP2022523513A5 (enExample) | ||
| HRP20250097T1 (hr) | Primjena tradipitanta kod bolesti kretanja | |
| JP2018529666A5 (enExample) | ||
| JP2018199643A5 (enExample) | ||
| FR2974729A1 (fr) | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent | |
| JP2015512420A5 (enExample) | ||
| Amery et al. | Prevention of the last chance: an alternative pharmacologic treatment of migraine | |
| JP2018505901A5 (enExample) | ||
| CN115515590A (zh) | 马赛替尼用于治疗多发性硬化患者亚群 | |
| WO2012102645A3 (en) | Pharmaceutical composition comprising the peptide glu-asp-gly and use for treating helicobacter pylori induced gastroduodenal diseases | |
| US20150126611A1 (en) | 3,3-diphenyl-n-(1-phenylethyl) propan-1-amine: as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity | |
| CN107921024B (zh) | 治疗或预防急性脑损伤或神经损伤的方法 |